Literature DB >> 20097678

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Mahmoud A Pouladi1, Yuanyun Xie, Niels Henning Skotte, Dagmar E Ehrnhoefer, Rona K Graham, Jeong Eun Kim, Nagat Bissada, X William Yang, Paolo Paganetti, Robert M Friedlander, Blair R Leavitt, Michael R Hayden.   

Abstract

Levels of full-length huntingtin (FL htt) influence organ and body weight, independent of polyglutamine length. The growth hormone-insulin like growth factor-1 (GH-IGF-1) axis is well established as a regulator of organ growth and body weight. In this study, we investigate the involvement of the IGF-1 pathway in mediating the effect of htt on body weight. IGF-1 expression was examined in transgenic mouse lines expressing different levels of FL wild-type (WT) htt (YAC18 mice), FL mutant htt (YAC128 and BACHD mice) and truncated mutant htt (shortstop mice). We demonstrate that htt influences body weight by modulating the IGF-1 pathway. Plasma IGF-1 levels correlate with body weight and htt levels in the transgenic YAC mice expressing human htt. The effect of htt on IGF-1 expression is independent of CAG size. No effect on body weight is observed in transgenic YAC mice expressing a truncated N-terminal htt fragment (shortstop), indicating that FL htt is required for the modulation of IGF-1 expression. Treatment with 17beta-estradiol (17beta-ED) lowers the levels of circulating IGF-1 in mammals. Treatment of YAC128 with 17beta-ED, but not placebo, reduces plasma IGF-1 levels and decreases the body weight of YAC128 animals to WT levels. Furthermore, given the ubiquitous expression of IGF-1 within the central nervous system, we also examined the impact of FL htt levels on IGF-1 expression in different regions of the brain, including the striatum, cerebellum of YAC18, YAC128 and littermate WT mice. We demonstrate that the levels of FL htt influence IGF-1 expression in striatal tissues. Our data identify a novel function for FL htt in influencing IGF-1 expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097678      PMCID: PMC2846162          DOI: 10.1093/hmg/ddq026

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  71 in total

1.  Nutritional evaluation of Huntington disease patients.

Authors:  L M Morales; J Estévez; H Suárez; R Villalobos; L Chacín de Bonilla; E Bonilla
Journal:  Am J Clin Nutr       Date:  1989-07       Impact factor: 7.045

2.  Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype.

Authors:  J G Hodgson; D J Smith; K McCutcheon; H B Koide; K Nishiyama; M B Dinulos; M E Stevens; N Bissada; J Nasir; I Kanazawa; C M Disteche; E M Rubin; M R Hayden
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

3.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids.

Authors:  B A Littlefield; E Gurpide; L Markiewicz; B McKinley; R B Hochberg
Journal:  Endocrinology       Date:  1990-12       Impact factor: 4.736

5.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.

Authors:  Y Trottier; Y Lutz; G Stevanin; G Imbert; D Devys; G Cancel; F Saudou; C Weber; G David; L Tora
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

6.  Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form.

Authors:  Y Trottier; D Devys; G Imbert; F Saudou; I An; Y Lutz; C Weber; Y Agid; E C Hirsch; J L Mandel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

7.  Expression of the Huntington's disease (IT15) protein product in HD patients.

Authors:  G Schilling; A H Sharp; S J Loev; M V Wagster; S H Li; O C Stine; C A Ross
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

8.  Abnormal gene product identified in Huntington's disease lymphocytes and brain.

Authors:  K Ide; N Nukina; N Masuda; J Goto; I Kanazawa
Journal:  Biochem Biophys Res Commun       Date:  1995-04-26       Impact factor: 3.575

9.  Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies.

Authors:  C A Gutekunst; A I Levey; C J Heilman; W L Whaley; H Yi; N R Nash; H D Rees; J J Madden; S M Hersch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.

Authors:  D A Shewmon; J L Stock; C J Rosen; K M Heiniluoma; M M Hogue; A Morrison; E M Doyle; T Ukena; V Weale; S Baker
Journal:  Arterioscler Thromb       Date:  1994-10
View more
  38 in total

1.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

2.  Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.

Authors:  Luana Naia; I Luísa Ferreira; Teresa Cunha-Oliveira; Ana I Duarte; Márcio Ribeiro; Tatiana R Rosenstock; Mário N Laço; Maria J Ribeiro; Catarina R Oliveira; Frédéric Saudou; Sandrine Humbert; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2014-05-20       Impact factor: 5.590

3.  Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Authors:  Sara Valdeolivas; Carmen Navarrete; Irene Cantarero; María L Bellido; Eduardo Muñoz; Onintza Sagredo
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 4.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

5.  IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease.

Authors:  Marianna Sadagurski; Zhiyong Cheng; Aldo Rozzo; Isabella Palazzolo; Gregory R Kelley; Xiaocheng Dong; Dimitri Krainc; Morris F White
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

Review 6.  Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.

Authors:  C Y Daniel Lee; Jeffrey P Cantle; X William Yang
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

7.  Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo.

Authors:  Robert O'Brien; Francesco DeGiacomo; Jennifer Holcomb; Akilah Bonner; Karen L Ring; Ningzhe Zhang; Khan Zafar; Andreas Weiss; Brenda Lager; Birgit Schilling; Bradford W Gibson; Sylvia Chen; Seung Kwak; Lisa M Ellerby
Journal:  J Biol Chem       Date:  2015-05-29       Impact factor: 5.157

8.  Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Authors:  Jing Jin; Jennifer Albertz; Zhihong Guo; Qi Peng; Gay Rudow; Juan C Troncoso; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2013-03-05       Impact factor: 5.372

9.  A fully humanized transgenic mouse model of Huntington disease.

Authors:  Amber L Southwell; Simon C Warby; Jeffrey B Carroll; Crystal N Doty; Niels H Skotte; Weining Zhang; Erika B Villanueva; Vlad Kovalik; Yuanyun Xie; Mahmoud A Pouladi; Jennifer A Collins; X William Yang; Sonia Franciosi; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2012-09-21       Impact factor: 6.150

10.  Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Authors:  Michal Wegrzynowicz; Terry Jo Bichell; Barbara D Soares; Meredith K Loth; Jennifer S McGlothan; Susumu Mori; Fatima S Alikhan; Kegang Hua; Jennifer M Coughlin; Hunter K Holt; Christopher S Jetter; Martin G Pomper; Alexander P Osmand; Tomás R Guilarte; Aaron B Bowman
Journal:  J Huntingtons Dis       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.